Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Omega Fund Management sold 411,968 Alumis shares in Q1, worth an estimated $10.3 million, leaving 241,255 shares valued at $5.31 million and reducing the position’s quarter-end value by $1.06 million. The stake still represents 3.3% of AUM, suggesting portfolio rebalancing or profit-taking rather than a conviction break. Alumis remains a biotech story driven by late-stage psoriasis and lupus data, with $569.5 million in cash funding operations into late 2027.

Analysis

This is less a bearish read-through on the name than a signal that a large biotech holder is actively de-risking into strength. When a fund trims a position after a multi-bagger run but keeps it in the top tier of holdings, the marginal message is usually that upside is now more execution-dependent than multiple-dependent; in other words, the easy money phase is over and the stock becomes hypersensitive to next two catalysts rather than broad sentiment.

The deeper implication is for competing TYK2/autoimmune assets: once a lead program posts credible late-stage psoriasis data, the market stops rewarding platform breadth and starts demanding differentiation on efficacy durability, dosing convenience, and safety cleanly enough to win formulary access. That raises the bar for peers with similar mechanisms, because any mixed readout later this year could compress the entire sub-sector, not just this stock, as investors rotate toward better-capitalized or nearer-term commercialization stories.

From a flow perspective, the stock’s recent vertical move creates a vulnerable setup: realized gains from holders like this increase the probability of additional supply on rallies, while the company’s cash runway reduces immediate financing risk but does not eliminate dilution over a multi-quarter horizon if the commercial path slips. The main overhang is not liquidity today but the gap between promising clinical data and a marketable franchise; if upcoming lupus data fails to extend the psoriasis signal, the stock can re-rate sharply even before any FDA filing milestone.

The contrarian view is that the market may be underpricing the probability of a near-term continuation squeeze if the next readout confirms the current efficacy profile. In that scenario, the combination of limited fundamental float, high biotech beta, and still-strong clinical optionality could keep momentum buyers in control for weeks, even if longer-term fundamental investors are harvesting gains now.

Key Decisions for Investors

• Short-dated call spread in ALMS into the next clinical catalyst: structure for upside continuation over the next 4-8 weeks, but cap premium because post-data implied volatility is likely elevated and supply from profit-takers can dampen follow-through.
• Pair trade: long ALMS vs short a basket of earlier-stage autoimmune TYK2/readout names over the next 1-3 months; ALMS has the cleaner de-risked setup, while weaker peers should suffer if the market narrows its tolerance for incremental mechanism risk.
• If already long ALMS, sell 20-30% of exposure on strength above recent highs and retain a core position into FDA submission timing; the risk/reward shifts from valuation expansion to binary execution.
• Avoid initiating fresh outright longs after a 300% run unless entering on a post-event pullback of at least 10-15%; the stock is now more likely to trade on catalyst cadence than on broad biotech sentiment.
• Use ALMS as a sentiment barometer for the autoimmune bucket: if the next data point disappoints, rotate toward better-capitalized commercial biopharma names and hedge basket exposure with a short in high-beta clinical-stage names.